Successful pregnancy outcome of nonimmune hydrops fetalis due to parvovirus B19


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Background. Parvovirus B19 infection during pregnancy can lead to nonimmune hydrops fetalis (NIHF), a condition characterized by a high perinatal mortality. Clinical case report. The paper describes a clinical case of NIHF caused by parvovirus B19 with a favorable outcome during treatment. The main therapeutic methods for antenatal exposure, which include drug and fetal surgical treatments, are depicted. The applied integrated approach could not only prolong pregnancy to full term, but also led to a significant intrauterine reversal of NIHF phenomena. Conclusion. This clinical case demonstrates the need for further study of the problem of NIHF and for the selection of therapeutic measures based on the determination of an etiological factor. Such an approach contributes to the selection of optimal management tactics for pregnancy, delivery, and neonatal care.

全文:

受限制的访问

作者简介

Faina Kadyrberdieva

Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: f_kadyrberdieva@oparina4.ru

Nana Tetruashvili

Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: n_tetruashvili@oparina4.ru

Roman Shmakov

Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: r_shmakov@oparina4.ru

Ekaterina Bokeria

Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: e_bokeriya@oparina4.ru

Kirill Kostyukov

Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: k_kostyukov@oparina4.ru

Lydmila Kim

Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: l_kim@oparina4.ru

Oksana Bystrykh

Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: o_bystrykh@oparina4.ru

Andrey Donnikov

Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: a_donnikov@oparina4.ru

Yuliya Podurovskaya

Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: y_podurovskaya@oparina4.ru

参考

  1. Cossart Y.E., Field A.M., Cant B., Widdows D. Parvovirus-like particles in human sera. Lancet 1975; 1:72-73. doi: 10.1016/s0140-6736(75)91074-0
  2. Anderson M.J., Jones S.E., Fisher-Hoch S.P., LewisE., Hall S.M., Bartlett C.L., et al. Human parvovirus, the cause of erythema infectiosum (fifth disease). Lancet. 1983; 1:1378.
  3. Mossong J. Parvovirus B19 infection in five European countries: seroepidemiology, force of infection and maternal risk of infection. J Epidemiol Infect. 2008; 136:1059-68. doi: 10.1017/S0950268807009661
  4. de Jong E.P, Walther F.J., Kroes A.C., Oepkes D. Parvovirus B19 infection in pregnancy: new insights and management. Prenat Diagn. 2011; 31: 419-25. doi: 10.1002/pd.2714.
  5. Dijkmans A.C., de Jong E.P, Dijkmans B.A., Lopriore E., Vossen A., Walther F.J., et al. Parvovirus B19 in pregnancy: prenatal diagnosis and management of fetal complications. Curr Opin Obstet Gynecol. 2012; 24: 95-101. doi: 10.1097/ GCO.0b013e3283505a9d.
  6. Anderson L.J. Role of parvovirus B19 in human disease. Pediatr Infect Dis J. 1987; 6: 711-8. doi: 10.1097/00006454-198708000-00003
  7. Markenson G.R., Yancey M.K. Parvovirus B19 infections in pregnancy. Semin Perinatol. 1998; 22: 309-17. doi: 10.1016/s0146-0005(98)80019-0
  8. Lamont R.F, Sobel J.D., Vaisbuch E., Kusanovic J.P., Mazaki-Tovi S., Kim S.K. et. al. Parvovirus B19 infection in human pregnancy. BJOG. 2011; 118: 175-86. doi: 10.1111/j.1471-0528.2010.02749.x.
  9. Valeur-Jensen A.K., Pedersen C.B., Westergaard T., Jensen I.P., Lebech M., Andersen P.K., et al. Risk factors for parvovirus B19 infection in pregnancy. JAMA. 1999; 281: 1099-1105. doi: 10.1001/ jama.281.12.1099
  10. Nunoue T., Kusuhara K., Hara T. Human fetal infection with parvovirus B19: maternal infection time in gestation, viral persistence and fetal prognosis. Pediatr Infect Dis J. 2002; 21:1133-6. doi: 10.1097/00006454-200212000-00009
  11. ВасильевВ.В., Мурина Е.А., Сидоренко С.В., Мукомолова А.Л. Парвовирусная (B19V) инфекция у беременных и детей раннего возраста. Журнал инфектологии. 2011; 34: 26-33. [Vasiliev V.V., Murina E.A., Sidorenko S.V., Mukomolova A.L. Parvovirus (B19V) infection in pregnant women and young children. Journal of Infectology. 2011; 34: 26-33. (in Russian)]. eLIBRARY ID: 17707424
  12. Reid D.M., Reid T.M., Brown T., Rennie J.A., Eastmond C.J. Human parvovirus-associated arthritis: a clinical and laboratory description. Lancet. 1985; 1: 422-5. doi: 10.1016/s0140-6736(85)91146-8
  13. Servant-Delmas. Advances in human B19 erythrovirus biology. J Virol. 2010; 9658-65. doi: 10.1128/JVI.00684-10.
  14. Jones M.S. New DNA viruses identified in patients with acute viral infection syndrome. J. Virol. 2005; 79: 8230-6. doi: 10.1128/JVI.79.13.8230-8236.2005
  15. Malm C., Fridell E., Jansson K. Heart failure after parvovirus B19 infection. Lancet. 1993; 341:1408-9. doi: 10.1016/0140-6736(93)90973-k
  16. Leduc L.; SOGC Maternal-Fetal Medicine Committee. Stillbirth and bereavement: guidelines for stillbirth investigation. SOGC Clinical Practice Guidelines, No. 178, 2006. J Obstet Gynaecol Can. 2006; 28: 540-52. doi: 10.1016/S1701-2163(16)32172-7
  17. Watt A.P., Brown M., Pathiraja M., Anbazhagan A., Coyle P.V. The lack of routine surveillance of parvovirus B19 infection in pregnancy prevents an accurate understanding of this regular cause of fetal loss and the risks posed by occupational exposure. J Med Microbiol. 2013; 62(Pt 1): 86-92. doi: 10.1099/ jmm.0.046714-0.
  18. Harger J.H., Adler S.P., Koch W.C., Harger G.F. Prospective evaluation of 618 pregnant women exposed to parvovirus B19: risks and symptoms. Obstet Gynecol. 1998; 91: 413-20. doi: 10.1016/s0029-7844(97)00701-1
  19. Simms R.A., Liebling R.E., Patel R.R., Denbow M.L., Abdel-Fattah S.A., Soot hill P.W. et al. Management and outcome of pregnancies with parvovirus B19 infection over seven years in a tertiary fetal medicine unit. Fetal Diagn Ther. 2009; 25: 373-8. doi: 10.1159/000236149.
  20. Козлов П.В., Кузнецов П.А., Леонова Е.И., Константинова К.И. Неиммунная водянка плода. Современный взгляд на проблемы этиологии, патогенеза и перинатального исхода. Проблемы репродукции. 2014; 83-7. [Kozlov P.V., Kuznetsov P.A., Leonova E.I., Konstantinova K.I. Non immune hydrops fetalis. A modern review of the problems of etiology, pathogenesis and perinatal outcome. Reproduction problems. 2014; 83-7. (in Russian)].
  21. Crane J., St. John’s N.L., Mundle W., Windsor O.N., Boucoiran I., Vancouver B.C. Parvovirus B19 Infection in Pregnancy. J Obstet Gynaecol Can. 2014; 36(12):1107-16. http://dx.doi.org/10.1016/S1701-2163(15)30390-X
  22. Колобов А.В., Карев В.Е., Воробцова И.Н., Орел В.И. Неиммунный отек плода при внутриутробной инфекции. Журнал инфектологии. 2013; 109-112. [Kolobov A.V., Karev V.E., Vorobtsova I.N., Orel V.I. Non immune hydrops fetalis with intrauterine infection. Journal of Infectology. 2013; 109-112. (in Russian)].
  23. Enders M., Schalasta G., Baisch C., Weidner A., Pukkila L., Kaikkonen L. et al. Human parvovirus B19 infection during pregnancy-value of modern molecular and serological diagnostics. J Clin Virol. 2006; 35: 400-6. doi: 10.1016/ j.jcv.2005.11.002
  24. Desilets V., Sherbrooke Q.C., De Bie I., et al. No. 363-Investigation and Management of Non-immune Fetal Hydrops. J Obstet Gynecol Can. 2018; 40(8):1077-90. doi: 10.1016 / j.jogc.2017.12.011
  25. Mary E.N., Suneet P.C., Jodi S.D. Society for Maternal-Fetal Medicine (SMFM) Clinical Guideline#7:nonimmune hydrops fetalis. Am J Obstet Gynecol. 2015. http://dx.doi.org/10.1016/j.ajog.2014.12.018
  26. Fairley C.K., Smoleniec J.S., Caul O.E., Miller E. Observational study of effect of intrauterine transfusions on outcome of fetal hydrops after parvovirus B19 infection. Lancet. 1995; 346:1335-7. doi: 10.1016/s0140-6736(95)92346-2
  27. von Kaisenberg C.S., Jonat W. Fetal parvovirus B19 infection. Ultrasound Obstet Gynecol. 2001; 18: 280-8. doi: 10.1046/j.1469-0705.2001.00471.x
  28. Nigro G., Adler S.P., La Torre R., Best A.M. Passive immunization during pregnancy for congenital cytomegalovirus infection. N. Engl J. Med. 2005; 353: 1350-62. doi: 10.1056/NEJMoa043337
  29. Matsuda H., Sakaguchi K., Shibasaki T., Takahashi H., Kawakami Y., Furuya K. Intrauterine therapy for parvovirus B19 infected symptomatic fetus using B19 IgG-rich high titer gammaglobulin. J. Perinat Med. 2005; 561-3. doi: 10.1515/ JPM.2005.100
  30. Смирнов А.В., Бологов А.А., Брюсова И.Б., Волкова Г.И., Ильина Е.С. Применение Октагама при тяжелых инфекционных заболеваниях у детей. Детские инфекции. 2003; 40-4.
  31. Society for Maternal-Fetal Med Fetal blood sampling. Am J. Obstet Gynecol. 2013; 5: 170-80. doi: 10.1016/j.ajog.2013.07.014
  32. Беспалова Е.Д., Бокерия Е.Л. Перинатальный кардиологический скрининг - методические рекомендации для врачей неонатологов, педиатров, акушеров-гинекологов, врачей функциональной диагностики. Вопросы практической педиатрии. 2010; 5 (1): 60-2.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2020
##common.cookie##